39548-89-5

Usage

Preparation

Preparation by reaction of benzyl chloride on 2,4-dihydroxy-6-methoxyacetophenone with potassium carbonate in boiling acetone.

Upstream product

• 3602-54-8 4,6-dihydroxy-2-methoxyacetophenone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 681294-57-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethanone 
• 110506-85-9 7-(benzyloxy)-5-hydroxy-2-phenyl-4H-chromen-4-one 
• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 77-78-1 dimethyl sulfate 
• 480-66-0 2,4,6-trihydroxyacetophenone 

Downstream Products

• 84457-62-5 2'-hydroxy-4'-benzyloxy-4,6'-dimethoxychalkone 
• 84457-62-5 (E)-1-(4-Benzyloxy-2-hydroxy-6-methoxy-phenyl)-3-(4-methoxy-phenyl)-propenone 
• 69888-33-1 7-benzyloxy-4-hydroxy-5-methoxycoumarin 
• 76609-41-1 ethyl 7-benzyloxy-4-hydroxy-5-methoxy-3-carboxylate 
• 1139263-23-2 (1R,2R,3S,3aR,8bS)-methyl 3a-(4-cyanophenyl)-1,8b-dihydroxy-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]-cyclopenta[d]furan-2-carboxylate 
• 1402931-89-8 C₃₈H₃₈O₁₁ 
• 1402931-83-2 (1R,2R,3S,3aR,8bS)-1,8b-dihydroxy-6-((2S,6S)-6-(hydroxymethyl)-1,4-dioxan-2-yloxy)-8-methoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]-furan-2-carboxamide 
• 1402931-84-3 (1R,2R,3S,3aR,8bS)-6-cyano-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-2-carboxamide 
• 1402931-85-4 (1R,2R,3S,3aR,8bS)-6-chloro-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-2-carboxamide 
• 1139263-21-0 (1R,2R,3S,3aR,8bS)-3a-(4-cyanophenyl)-1,8b-dihydroxy-6,8-dimethoxy-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo-[b]cyclopenta[d]furan-2-carboxamide 
• 1402931-30-9 7-(benzyloxy)-5-methoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-3-yl 4-methoxybenzoate 
• 874202-33-2 7-(benzyloxy)-3-hydroxy-5-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
• 960365-65-5 (1R,2R,3S,3aR,8bS)-methyl 1,6,8b-trihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]-cyclopenta[d]furan-2-carboxylate 
• 1402931-90-1 C₂₇H₂₃NO₇ 

Relevant academic research and scientific papers

AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES

Compounds are described with the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and n are defined as anywhere herein, which are useful for the treatment of cancer and other dysproliferative diseases.

Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same

The present invention relates to a novel compound and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. More specifically, the present invention relates to a novel compound of chemical formula 1 which has an excellent effect for prevention, improvement, or treatment of fibrosis and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. A novel compound of the present invention effectively controls expression of snail and vimentin which are a controlling element of Epithelial Mesenchymal Transition (EMT) and controls activation of EMT, and thus effectively prevents, improves, or treats fibrosis accordingly. Additionally, a novel compound of the present invention has a very excellent pharmacokinetic characteristic, and thus can perform fast drug delivery to the body through oral administration, stably displays an effect in the body, and is secure to use without a big side effect. Moreover, since a novel compound of the present invention can effectively block fibrosis of a hepatic cell, nonalcoholic steatohepatitis can effectively improved or treated.(AA) Chemical formula 1COPYRIGHT KIPO 2018

USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY

A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5′-untranslated region UTR) relative to simple 5′UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects

1 The functional characterization of hispidulin (4′,5,7-trihydroxy-6- methoxyflavone), a potent benzodiazepine (BZD) receptor ligand, was initiated to determine its potential as a modulator of central nervous system activity. 2 After chemical synthesis, hispidulin was investigated at recombinant GABA A/BZD receptors expressed by Xenopus laevis oocytes. Concentrations of 50 nM and higher stimulated the GABA-induced chloride currents at tested receptor subtypes (α 1-3,5,6β2γ2S) indicating positive allosteric properties. Maximal stimulation at α1β 2γ2S was observed with 10 μM hispidulin. In contrast to diazepam, hispidulin modulated the α6β 2γ2S-GABAA receptor subtype. 3 When fed to seizure-prone Mongolian gerbils (Meriones unguiculatus) in a model of epilepsy, hispidulin (10 mg kg-1 body weight (BW) per day) and diazepam (2 mg kg-1 BW per day) markedly reduced the number of animals suffering from seizures after 7 days of treatment (30 and 25% of animals in the respective treatment groups, vs 80% in the vehicle group). 4 Permeability across the blood-brain barrier for the chemically synthesized, 14C-labelled hispidulin was confirmed by a rat in situ perfusion model. With an uptake rate (Kin) of 1.14 ml min-1 g -1, measurements approached the values obtained with highly penetrating compounds such as diazepam. 5 Experiments with Caco-2 cells predict that orally administered hispidulin enters circulation in its intact form. At a concentration of 30 μM, the flavone crossed the monolayer without degradation as verified by the absence of glucuronidated metabolites.

Synthesis of a New Flavone

The structure of the naturally occuring flavone 5-O-methylacacetin (I) has been confirmed by its synthesis. 5,7-Di-O-methylacacetin has been synthesised.